GGrantIndex
← Leaderboards

Julien Sage

University Of California Santa Cruz

Google Scholar ↗PubMed ↗ORCID ↗
$21,311,801
Attributed
$29,538,442
Total exposure
17
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY2006–25
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$29,538,442 · 17

By mechanism

R01$13,981,098 · 7
R35$6,180,738 · 1
T32$3,550,875 · 1
U01$3,038,770 · 1
P01$1,943,409 · 4
R21$830,784 · 2

Top collaborators

Most similar at University Of California Santa Cruz

Same institution · by research overlap

Others in their field

Top investigators on “Cells”

Research focus

CellsTumorGeneticMalignant NeoplasmsIn VivoMolecularResponsePathway InteractionsMouse ModelGrowthCancer CellGenesBaseInsightSignal TransductionGenetic TranscriptionFamilyMutationTumor Suppressor ProteinsMutantNeoplastic CellProteinsBiochemicalPrevent

Grant awards (69)

Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies$959,562
R35 · FY2025 · CA · contact PI
Modulating cysteine metabolism to induce cell death in small cell lung cancer$530,786
R01 · FY2025 · CA
Leveraging innovative technologies in basic and clinical cancer research$395,249
T32 · FY2025 · CA
Project 2: To determine the consequences of activating Rb function in cancer cells$236,085
P01 · FY2025 · CA · contact PI
Core A: Determining and targeting mechanisms controlling cancer cell division$236,084
P01 · FY2025 · CA · contact PI
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies$913,132
R35 · FY2024 · CA · contact PI
Modulating cysteine metabolism to induce cell death in small cell lung cancer$530,786
R01 · FY2024 · CA
Leveraging innovative technologies in basic and clinical cancer research$395,193
T32 · FY2024 · CA
Core A: Determining and targeting mechanisms controlling cancer cell division$224,720
P01 · FY2024 · CA · contact PI
Project 2: To determine the consequences of activating Rb function in cancer cells$224,720
P01 · FY2024 · CA · contact PI
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies$943,287
R35 · FY2023 · CA · contact PI
Leveraging innovative technologies in basic and clinical cancer research$406,309
T32 · FY2023 · CA
Molecular basis of tumor suppression by Cdk4/6 inhibition$347,343
R01 · FY2023 · CA
Core A: Determining and targeting mechanisms controlling cancer cell division$234,396
P01 · FY2023 · CA · contact PI
Project 2: To determine the consequences of activating Rb function in cancer cells$234,396
P01 · FY2023 · CA · contact PI
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies$946,062
R35 · FY2022 · CA · contact PI
Cancer Etiology, Prevention, Detection and Diagnosis$499,634
T32 · FY2022 · CA
Molecular basis of tumor suppression by Cdk4/6 inhibition$349,699
R01 · FY2022 · CA
Core A: Determining and targeting mechanisms controlling cancer cell division$276,504
P01 · FY2022 · CA · contact PI
Project 2: To determine the consequences of activating Rb function in cancer cells$276,504
P01 · FY2022 · CA · contact PI
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies$964,611
R35 · FY2021 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$551,067
U01 · FY2021 · CA
Cancer Etiology, Prevention, Detection and Diagnosis$466,869
T32 · FY2021 · CA
Molecular basis of tumor suppression by Cdk4/6 inhibition$359,169
R01 · FY2021 · CA
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies$963,873
R35 · FY2020 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$702,580
U01 · FY2020 · CA
Cancer Etiology, Prevention, Detection and Diagnosis$459,486
T32 · FY2020 · CA
Molecular basis of tumor suppression by Cdk4/6 inhibition$361,407
R01 · FY2020 · CA
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$573,659
U01 · FY2019 · CA
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies$490,211
R35 · FY2019 · CA · contact PI
Cancer Etiology, Prevention, Detection and Diagnosis$479,110
T32 · FY2019 · CA
Molecular and cellular mechanisms of SCLC metastasis$397,500
R01 · FY2019 · CA · contact PI
Molecular basis of tumor suppression by Cdk4/6 inhibition$377,097
R01 · FY2019 · CA
Notch signaling in small cell lung carcinoma$361,879
R01 · FY2019 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$596,039
U01 · FY2018 · CA
Cancer Etiology, Prevention, Detection and Diagnosis$449,025
T32 · FY2018 · CA
Molecular and cellular mechanisms of SCLC metastasis$409,796
R01 · FY2018 · CA · contact PI
Notch signaling in small cell lung carcinoma$372,322
R01 · FY2018 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$615,425
U01 · FY2017 · CA
Mechanisms of action of the Smyd3 methyltransferase in cancer cells$457,506
R01 · FY2017 · CA
Molecular and cellular mechanisms of SCLC metastasis$441,854
R01 · FY2017 · CA · contact PI
Notch signaling in small cell lung carcinoma$371,618
R01 · FY2017 · CA · contact PI
Chromatin changes in the thymus epithelium during aging$242,730
R21 · FY2017 · AG · contact PI
Mechanisms of action of the Smyd3 methyltransferase in cancer cells$457,506
R01 · FY2016 · CA
Molecular and cellular mechanisms of SCLC metastasis$409,796
R01 · FY2016 · CA · contact PI
Notch signaling in small cell lung carcinoma$370,960
R01 · FY2016 · CA · contact PI
The RB pathway in liver cancer$278,578
R01 · FY2016 · CA · contact PI
Chromatin changes in the thymus epithelium during aging$217,429
R21 · FY2016 · AG · contact PI
Mechanisms of action of the Smyd3 methyltransferase in cancer cells$457,506
R01 · FY2015 · CA
The RB pathway in liver cancer$278,271
R01 · FY2015 · CA · contact PI
Mechanisms of action of the Smyd3 methyltransferase in cancer cells$443,781
R01 · FY2014 · CA
The RB pathway in liver cancer$269,636
R01 · FY2014 · CA · contact PI
Mechanisms of action of the Smyd3 methyltransferase in cancer cells$477,053
R01 · FY2013 · CA
The RB pathway in liver cancer$261,030
R01 · FY2013 · CA · contact PI
Molecular and cellular mechanisms of Merkel Cell Carcinoma development$196,177
R21 · FY2013 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$521,052
R01 · FY2012 · CA
The RB pathway in liver cancer$277,418
R01 · FY2012 · CA · contact PI
Molecular and cellular mechanisms of Merkel Cell Carcinoma development$174,448
R21 · FY2012 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$536,945
R01 · FY2011 · CA
METHYLATION OF THE RETINOBLASTOMA TUMOR SUPPRESSOR BY SMYD2$12,768
P41 · FY2011 · RR · contact PI
Comparative functional genomics for lung cancer gene discovery$569,332
R01 · FY2010 · CA
The RB Gene Family in Cancer Initiation$278,388
R01 · FY2010 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$573,992
R01 · FY2009 · CA
The RB Gene Family in Cancer Initiation$278,016
R01 · FY2009 · CA · contact PI
The RB Gene Family in Cancer Initiation$165,320
R01 · FY2009 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$574,485
R01 · FY2008 · CA
The RB Gene Family in Cancer Initiation$277,675
R01 · FY2008 · CA · contact PI
The RB Gene Family in Cancer Initiation$274,504
R01 · FY2007 · CA · contact PI
The RB Gene Family in Cancer Initiation$281,092
R01 · FY2006 · CA · contact PI